E Barrett-Connor1, K Ensrud, A N A Tosteson, S F Varon, M Anthony, N Daizadeh, S Wade. 1. Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0607, USA. ebarrettconnor@ucsd.edu
Abstract
UNLABELLED: Failure to take prescribed medication is common. The POSSIBLE US study is evaluating the impact of physician and patient characteristics on patient-reported compliance and persistence with osteoporosis medications. We report our study design and the baseline characteristics of 4,994 postmenopausal women recruited from primary care physician offices in 33 states. INTRODUCTION: The Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US) is a longitudinal cohort study of osteoporosis therapy in primary care. METHODS: Between 2004 and 2007, 134 physicians (in 33 states) enrolled postmenopausal women initiating, changing, or continuing osteoporosis medications. After completing a baseline questionnaire, participants will provide data semi-annually for up to 3 years through 2008. Physicians provide patient data at baseline and routine follow-up visits. Participants from 23 sites also signed a release regarding administrative claims data for economic analyses and validation of self-reported data. BASELINE RESULTS: Four thousand nine hundred and ninety-four evaluable women were recruited from internal medicine (n = 1,784), family practice (n = 1,556), obstetrics/gynecology (n = 1,556), and from one rheumatology practice (n = 98). Mean participant age was 64.3 years (SD = 9.97); 89% were Caucasian; 59% had some college education. Sixty-three percent used a single osteoporosis agent, usually a bisphosphonate. For monotherapy patients, concordance between clinic- and patient-reported medication use was lowest for patients prescribed estrogen therapy (70%) or calcium/vitamin D (72%). Obstetrician/gynecologists enrolled younger women, who were more likely to use estrogen therapy than patients enrolled by other physicians. The 934 women (19%) prescribed only calcium/vitamin D were younger than women prescribed pharmacologic therapy. CONCLUSIONS: POSSIBLE US provides a unique foundation for evaluating longitudinal use of osteoporosis medications and related outcomes.
UNLABELLED: Failure to take prescribed medication is common. The POSSIBLE US study is evaluating the impact of physician and patient characteristics on patient-reported compliance and persistence with osteoporosis medications. We report our study design and the baseline characteristics of 4,994 postmenopausal women recruited from primary care physician offices in 33 states. INTRODUCTION: The Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US) is a longitudinal cohort study of osteoporosis therapy in primary care. METHODS: Between 2004 and 2007, 134 physicians (in 33 states) enrolled postmenopausal women initiating, changing, or continuing osteoporosis medications. After completing a baseline questionnaire, participants will provide data semi-annually for up to 3 years through 2008. Physicians provide patient data at baseline and routine follow-up visits. Participants from 23 sites also signed a release regarding administrative claims data for economic analyses and validation of self-reported data. BASELINE RESULTS: Four thousand nine hundred and ninety-four evaluable women were recruited from internal medicine (n = 1,784), family practice (n = 1,556), obstetrics/gynecology (n = 1,556), and from one rheumatology practice (n = 98). Mean participant age was 64.3 years (SD = 9.97); 89% were Caucasian; 59% had some college education. Sixty-three percent used a single osteoporosis agent, usually a bisphosphonate. For monotherapy patients, concordance between clinic- and patient-reported medication use was lowest for patients prescribed estrogen therapy (70%) or calcium/vitamin D (72%). Obstetrician/gynecologists enrolled younger women, who were more likely to use estrogen therapy than patients enrolled by other physicians. The 934 women (19%) prescribed only calcium/vitamin D were younger than women prescribed pharmacologic therapy. CONCLUSIONS: POSSIBLE US provides a unique foundation for evaluating longitudinal use of osteoporosis medications and related outcomes.
Authors: Timothy W Downey; Susan H Foltz; Stephen J Boccuzzi; Mohamed A Omar; Kristijan H Kahler Journal: South Med J Date: 2006-06 Impact factor: 0.954
Authors: Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman Journal: Mayo Clin Proc Date: 2006-08 Impact factor: 7.616
Authors: Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick Journal: Osteoporos Int Date: 2003-09-19 Impact factor: 4.507
Authors: Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín Journal: Clin Ther Date: 2004-02 Impact factor: 3.393
Authors: E Barrett-Connor; S W Wade; R W Downs; T Ganiats; M Hochberg; R R Recker; B S Stolshek Journal: Osteoporos Int Date: 2015-04-16 Impact factor: 4.507
Authors: E Barrett-Connor; S W Wade; T P Do; S Satram-Hoang; R Stewart; G Gao; D Macarios Journal: Osteoporos Int Date: 2011-04-06 Impact factor: 4.507
Authors: Jeffrey R Curtis; Qian Cai; Sally W Wade; Bradley S Stolshek; John L Adams; Akhila Balasubramanian; Hema N Viswanathan; Joel D Kallich Journal: Bone Date: 2013-03-15 Impact factor: 4.398
Authors: F Guillemin; L Martinez; M Calvert; C Cooper; T Ganiats; M Gitlin; R Horne; A Marciniak; J Pfeilschifter; S Shepherd; A Tosteson; S Wade; D Macarios; N Freemantle Journal: Osteoporos Int Date: 2013-06-11 Impact factor: 4.507